Posted by Michael Wonder on 09 Oct 2018
Health Canada approves new indications for Xeljanz in ulcerative colitis & psoriatic arthritis
9 October 2018 - Xeljanz, an oral therapy, is the first and only Janus kinase inhibitor approved by Health Canada for rheumatoid arthritis, ulcerative colitis and psoriatic arthritis.
Pfizer Canada has announced the Health Canada approval of Xeljanz for two new indications: the treatment of adult patients with moderately to severely active ulcerative colitis, and the treatment of adult patients with active psoriatic arthritis.
Xeljanz was previously approved in 2014 for the treatment of rheumatoid arthritis.
